The American College of Radiology has advised doctors to avoid using three specific types of common gadolinium-based contrast agents when administering MRIs. 

According to an advisory from the ACR, three common contrast agents -  gadodiamide or Omniscan by GE Healthcare, gadopentetate dimeglumine or Magnevist by Bayer Healthcare Pharmaceuticals, and Gadoversetamide by OptiMARK by Covidien - are linked with a greater number of nephrogenic systemic fibrosis cases. As of December 2009, NSF disease has been documented in 382 patients who received gadodiamide, out of 13 million doses; 195 patients who received gadopentetate dimeglumine, out of 23 million doses; and in 35 patients who received gadoversetamide, out of 4.7 million doses, according to the United States Food and Drug Administration. 

Nephrogenic systemic fibrosis is an extremely rare and incurable condition. Richard Cohan, MD, professor of abdominal radiology at the University of Michigan said that of all the patients who receive gadolinium with an MRI "more than 90 percent... will not develop NSF."

If you or someone you love has been diagnosed with Nephrogenic Systemic Fibrosis, or NSF, and a gadolinium-based contrast agent used in an MRI scan may be to blame, you may be entitled to compensation for your injuries and suffering. Know your rights and a options, and be sure you are in contact with an experience legal team. If you need advice, contact the gadolinium attorneys of Williams Kherkher at 800-761-3187 today.